ClinicalTrials.gg
RecruitingNCT07734181Updated Jul 30, 2026

Music Therapy in Parkinson's Disease

An interventional study of Music therapy in Parkinson's Disease (PD), sponsored by Siegward -M. Elsas. Recruiting at 1 site in Switzerland. Open to participants aged 50 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Siegward -M. Elsas · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
50 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Parkinson Disease with a site in Switzerland — 31 open to participants now, 34 under way, none of them phase 3. Parkinson Disease · Switzerland.

Planned enrollment
18th of 67
50 · median 30
Started
2026
with 4 others
No phase
49 of 85
23 open now
Primary completion
2028-09
later than 29 of 33 live
Registered
83rd of 85
by date

Among the 85 studies in Parkinson Disease with a site in Switzerland, this one is the 18th largest by planned enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2026, is one of 49 with no phase, reaches primary completion later than 29 of the 33 other live ones, and was the 83rd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

31 of the 85 studies in Parkinson Disease with a site in Switzerland are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Parkinson Disease with a site in Switzerland, or all of them as a file.
02

Study summary

This study aims to examine whether individual music therapy - involving the slow, gentle bowing of a string instrument, accompanied by the music therapist's singing and lyre playing - can have a relaxing and calming effect on patients with Parkinson's disease and improve anxiety, quality of life, and autonomic dysfunction such as unstable blood pressure.

People with Parkinson's disease often struggle with anxiety, apathy, and depression, which can severely affect their quality of life. These symptoms are usually difficult to treat adequately with medication. They are frequently associated with dysfunction of the autonomic nervous system and a reduced variability of heart rate. Both are common in Parkinson's disease and can provide clues about stress and well-being. A healthy heart does not beat at completely regular intervals; instead, the time between beats constantly changes slightly. This fluctuation is called heart rate variability (HRV).

Primary study outcome will be anxiety. Motivation, depression, individual quality of life, and severity of autonomic symptoms are also assessed using validated questionnaires.

Physical study measures will be HRV, along with stability of blood pressure, intensity of tremor, ability to walk, and also electroencephalography (EEG) to assess brain activity.

A subproject will explore whether listening to emotionally evocative music can specifically influence the brain in patients with Parkinson's disease (as measured by EEG) and autonomic functions (as measured by HRV). The effectiveness of an emotional response will be measured by a questionnaire (the Geneva Emotional Music Scale).

03

Conditions studied

  • Parkinson's Disease (PD)

Browse trials for

Keywords

  • Parkinson's disease
  • Music therapy
  • Anthroposophical music therapy
  • EEG
  • HRV
  • Parkinson Anxiety Scale (PAS)
04

Who can participate

Ages eligible
50 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parkinson's disease, Hoehn and Yahr stages 1-4
  • good understanding of the German language
  • Signed written

Exclusion criteria

Exclusion Criteria:

  • Previous music therapy within the last 12 months
  • Severe hearing impairment
  • Manifest dementia ( \< 20)
  • Severe physical disability
  • Severe somatic or psychiatric illness
  • Concurrent participation in another clinical trial targeting treatment of Parkinson's disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Music therapy intervention

    Other: Music therapy

Interventions

  • OtherMusic therapy

    Eight weekly individual sessions of music therapy for patients with Parkinson's disease. Part 1 - Listening to lyre music (10 minutes) Participants listen to emotionally stimulating lyre music. Part 2 - Active playing of a string instrument (20 minutes) Participants perform slow, calm bowing of a low string instrument, the Tenor Chrotta (with a pitch range comparable to the cello), guided and supported by the singing of the music therapist.

06

What researchers measure

Primary outcomes

  1. Parkinson Anxiety Scale (PAS)

    The Parkinson Anxiety Scale (PAS) is a 12-item, Parkinson's disease-specific rating scale that measures anxiety severity across three domains: persistent anxiety, episodic anxiety, and avoidance behavior. Items are rated on a 5-point Likert scale, with higher scores indicating greater anxiety.

    Time frame: From four weeks before the first treatment (pre-baseline), immediately before the first treatment (baseline), after weeks 4 and 8 of the weekly treatment, and 4 weeks after the end of therapy (follow-up), through study completion, on average 4 months.

Secondary outcomes

  1. Geriatric Depression Scale (GDS-15)

    The Geriatric Depression Scale-15 is a 15-item self-report questionnaire assessing depressive symptoms in older adults. Total scores range from 0 to 15, with higher scores indicating greater depression severity.

    Time frame: From four weeks before the first treatment (pre-baseline), immediately before the first treatment (baseline), after weeks 4 and 8 of the weekly treatment, and 4 weeks after the end of therapy (follow-up), through study completion, on average 4 months.

  2. Scales for Outcomes in Parkinson's disease - Autonomic Dysfunction (SCOPA-AUT)

    The Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA-AUT) is a 26-item self-report questionnaire assessing autonomic symptoms in patients with Parkinson's disease. Total scores range from 0 to 69, with higher scores indicating greater autonomic dysfunction.

    Time frame: From four weeks before the first treatment (pre-baseline), immediately before the first treatment (baseline), after weeks 4 and 8 of the weekly treatment, and 4 weeks after the end of therapy (follow-up), through study completion, on average 4 months.

  3. General Self-Efficacy Scale (SWE)

    The General Self-Efficacy Scale is a 10-item self-report questionnaire assessing optimistic beliefs about coping with difficult demands, problem solving, and adaptation to stressful life events. Total scores range from 10 to 40, with higher scores indicating greater general self-efficacy.

    Time frame: From four weeks before the first treatment (pre-baseline), immediately before the first treatment (baseline), after weeks 4 and 8 of the weekly treatment, and 4 weeks after the end of therapy (follow-up), through study completion, on average 4 months.

  4. Apathy Evaluation Scale (AES)

    The Apathy Evaluation Scale (AES) is an 18-item rating scale assessing apathy. Total scores range from 18 to 72, with higher scores indicating greater apathy.

    Time frame: From four weeks before the first treatment (pre-baseline), immediately before the first treatment (baseline), after weeks 4 and 8 of the weekly treatment, and 4 weeks after the end of therapy (follow-up), through study completion, on average 4 months.

  5. Schedule for the Evaluation of Individual Quality of Life (SEIQoL-Q)

    The Schedule for the Evaluation of Individual Quality of Life (SEIQoL-Q) is a 24-item rating scale assessing quality of life. Items are rated from from 0% to 100%, with higher scores indicating greater quality of life.

    Time frame: From four weeks before the first treatment (pre-baseline), immediately before the first treatment (baseline), after weeks 4 and 8 of the weekly treatment, and 4 weeks after the end of therapy (follow-up), through study completion, on average 4 months.

  6. Multidimensional Mood Questionnaire (MDBF)

    The Multidimensional Mood Questionnaire (MDBF) is a 12-item questionnaire used to assess current well-being before and after a music therapy session. Items are assessed on a 5-point Likert Scale form 1-5, with higher scores indicating stronger moods (positive or negative).

    Time frame: from the beginning of a therapy session to the end of a therapy session, on average over 45 minutes

  7. Heart Rate Variability (HRV)

    The degree of heart rate variability correlates with well-being, with lower values indicating an increase in stress and anxiety.

    Time frame: from onset of a therapy session to the end of a therapy session (avg. 45 min.), and 4 weeks before the 1st treatment, immediately before the 1st treatment, after weeks 4 and 8 of the weekly treatment, and 4 weeks after end of therapy (average 4 months).

Other outcomes

  1. modified Schellong test (orthostatic function)

    Continuous measurement of noninvasive blood pressure with the CNAP (Continuous Non-Invasive Arterial Pressure) machine from sitting to standing. Larger drops indicate more severe impairment of orthostatic regulation.

    Time frame: from onset of a therapy session to the end of a therapy session (avg. 45 min.), and 4 weeks before the 1st treatment, immediately before the 1st treatment, after weeks 4 and 8 of the weekly treatment, and 4 weeks after end of therapy (average 4 months).

  2. Timed up and Go Test (TUG)

    The Timed up and Go Test (TUG) measures the time in seconds needed to get up from a chair, walk 3 meters forward and back, and get seated again. The shorter the time needed, the better the ability to walk.

    Time frame: from onset of a therapy session to the end of a therapy session (avg. 45 min.), and 4 weeks before the 1st treatment, immediately before the 1st treatment, after weeks 4 and 8 of the weekly treatment, and 4 weeks after end of therapy (average 4 months).

  3. Tremor

    Tremor is item number 2.10 from the UPDRS-MDS (United Parkinson's Disease Rating Scale - Movement Disorders Society) questionnaire measuring severity of tremor by a 5 point Likert scale from 0 - 4, with higher scores indication more severe tremor

    Time frame: From four weeks before the first treatment (pre-baseline), immediately before the first treatment (baseline), after weeks 4 and 8 of the weekly treatment, and 4 weeks after the end of therapy (follow-up), through study completion, on average 4 months.

  4. Archimedes Spiral

    Drawing an Archimedes Spiral measures intensity of tremor; the greater the deviation from a regular spiral, the more severe is the tremor.

    Time frame: from onset of a therapy session to the end of a therapy session (avg. 45 min.), and 4 weeks before the 1st treatment, immediately before the 1st treatment, after weeks 4 and 8 of the weekly treatment, and 4 weeks after end of therapy (average 4 months).

  5. Electroencephalography (EEG)

    Power of alpha\&theta in cerebral regions and connectivity between cerebral regions will be measured.

    Time frame: from onset of a therapy session to the end of a therapy session (avg. 45 min.), during the 1st treatment, and during the last treatment (week 8 of the weekly treatment) (average 2 months).

  6. Geneva Emotional Music Scale (GEMS-9)

    The Geneva Emotional Music Scale (GEMS-9) is a 9-item questionnaire which rates the perceived emotions during listening to music, on a 5-point Likert scale from 1-5, with higher scores indicating stronger emotions (positive or negative). This scale is designed to measure how effective a piece of music has been to evoke specific emotions.

    Time frame: Some music therapy sessions include 4 sections of 5 min. each, which are designed to evoke specific emotions. At the end of each emotional music section, the GEMS-9 Scale measures how strong the experienced emotions were over the preceding 5 minutes.

07

Study locations

1 of 1 sites recruiting
  • Klinik Arlesheim AG
    Arlesheim, Basel-Landschaft 4144, Switzerland
    Recruiting
    • Siegward Elsas, Dr. med. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — this requirement is new to the PI and he will have to study its implications before agreeing to it

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Sep 2028, 26 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 26 months is close to that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2026
First posted
Jul 29, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 2, 2028
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07734181
Lead sponsor
Siegward -M. Elsas
Responsible party
Siegward -M. Elsas (Principal Investigator, Klinik Arlesheim) — Sponsor-investigator
First posted
Jul 29, 2026
Start date
Jun 2, 2026
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 2, 2028 (estimated)
Last update
Jul 30, 2026

Study contacts

Siegward Elsas, Dr. med.
Contact
Siegward.Elsas@klinik-arlesheim.ch
+41 61 705 71 13
Tiffany Huber, Msc.
Contact
tiffany.huber@klinik-arlesheim.ch
+41 61 705 71 55
Siegward Elsas, Dr. med.
principal investigator · Klinik Arlesheim

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion